Also known as edr peptide · Wikipedia
Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), one of the short 'bioregulator' peptides from the Khavinson family developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed in Russian and Eastern European literature for cognitive support, neuroprotection, and memory, with most published evidence coming from a single research group. Mechanistic studies report reduced oxidative stress, decreased neuronal apoptosis, and modulation of gene expression including S100B and dendritic-spine recovery in Alzheimer's disease models. No FDA approval and no clinical trials are registered on ClinicalTrials.gov. Treat all efficacy claims with caution. Also known as: EDR peptide.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR), one of the short 'bioregulator' peptides characterized by Khavinson and colleagues [Khavinson 2021, PMID 34071923]. The proposed mechanism is direct sequence-specific binding to gene-promoter regions to modulate transcription of neuroprotective factors including S100B [Ilina 2020, PMID 33396470].
Pharmacokinetic properties
Half-life
unknown (no rigorous human PK data published)
Routes
intramuscular · subcutaneous · oral · intranasal
Bioavailability
Khavinson group claims oral bioavailability; no Western PK validation. Small tripeptide size may permit some intestinal absorption but data is sparse.
Amino-acid sequence
Glu-Asp-Arg
Use & research dosing
No FDA-approved dose exists (research framing only). Self-experimentation protocols commonly use 100-200 mcg/day subcutaneously or intramuscularly in 10-20 day courses, sometimes repeated 2-4 times per year. Russian small observational reports have used 0.2 mg orally twice daily for 20-30 days. No standardized dosing exists outside the Khavinson institute literature, and no rigorous human PK or dose-response data is published in indexed Western journals.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Essentially all published Pinealon evidence originates with the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, which holds patents on the bioregulator-peptide class and commercializes them — a notable conflict of interest. The hypothesized mechanism (direct binding of a 3-residue peptide to gene promoters) is biophysically unusual and has not been independently replicated. Treat all efficacy claims with skepticism and prefer to use Pinealon as a hypothesis-generating compound rather than a validated therapeutic.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.